Orbenin-DC: Product Information

ORBENIN-DC- cloxacillin benzathine suspension
Merck Sharp & Dohme Corp.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Orbenin-DC (cloxacillin benzathine intramammary infusion) is a stable, nonirritating suspension of cloxacillin benzathine containing the equivalent of 500 mg of cloxacillin per disposable syringe. Orbenin-DC is manufactured by a nonsterilizing process.

Cloxacillin benzathine is a semisynthetic penicillin derived from the penicillin nucleus, 6-amino-penicillanic acid. Cloxacillin benzathine is the benzathine salt of 6-[3-(2-chlorophenyl)-5-methylisoxazolyl-4-carboxamido] penicillanic acid.

The low solubility of Orbenin-DC results in an extended period of activity. Therefore, directions for use should be followed explicitly.

ACTION: Cloxacillin benzathine is bactericidal in action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. It is active against gram-positive organisms associated with mastitis such as Staphylococcus aureus and Streptococcus agalactiae and, because of its resistance to penicillinase, penicillin G-resistant staphylococci which may be the cause of mastitis.

Appropriate laboratory tests should be conducted, including in vitro culturing and susceptibility tests on pretreatment milk samples collected aseptically.

SUSCEPTIBILITY TEST: The Kirby-Bauer 1 procedure, utilizing antibiotic susceptibility disks, is a quantitative method that may be adapted to determining the sensitivity of bacteria in milk to Orbenin-DC.

For testing the effectiveness of Orbenin-DC in milk, follow the Kirby-Bauer procedure using the 1 mcg oxacillin susceptibility disk. Zone diameters for interpreting susceptibility are:

Resistant Intermediate Susceptible
≤ 10 mm 11-12 mm ≥ 13 mm

1
Bauer AW, Kirby WMM, Sherris JC, et al: Antibiotic testing by a standardized single disk method, Am J Clin Path 45:493, 1966. Standardized Disk Susceptibility Test, Federal Register 37:20527–29, 1972.

INDICATIONS: Orbenin-DC is indicated in the treatment and prophylaxis of bovine mastitis in nonlactating cows due to Staphylococcus aureus and Streptococcus agalactiae.

CONTRAINDICATIONS: Because cloxacillin benzathine is relatively insoluble, Orbenin-DC’s activity will be prolonged. Therefore, Orbenin-DC should not be used for the occasional cow which may have a dry period of less than 4 weeks. This precaution will avoid residues in the milk following removal of the colostrum.

WARNINGS: For use in dry cows only. Do not use within 4 weeks (28 days) of calving. Treated animals must not be slaughtered for food purposes within 4 weeks (28 days) of treatment.

PRECAUTION: Because it is a derivative of 6-amino-penicillanic acid, Orbenin-DC has the potential for producing allergic reactions. Such reactions are rare; however, should they occur, the subject should be treated with the usual agents (antihistamines, pressor amines).

DOSAGE AND ADMINISTRATION: At the last milking of lactation, milk the cow out normally. Clean and disinfect the teats with alcohol swabs provided in the pail and infuse 1 syringe of Orbenin-DC, which has been warmed to room temperature, into each quarter. Do not milk out. The cow may be milked as usual when she calves.

The extent of subclinical and latent mastitis in a herd is frequently greater than suspected. In untreated herds a significant buildup of subclinical mastitis may occur during the dry period, which results in clinical severity after a few lactations. The adverse influence of subclinical mastitis on milk yield, the risk of cross-infection, and the chance of clinical mastitis flare-up make it necessary to treat the matter as a herd problem. Clinical studies have proven the value of treating all the cows in heavily infected herds as they are dried off. When the herd infection has been reduced, it may be desirable to be more selective in treating infected quarters.

Each pail contains 144 alcohol wipes to facilitate proper cleaning and disinfecting of the teat orifice.

HOW SUPPLIED: Orbenin-DC is supplied in pails of 144 single dose syringes with 144 alcohol wipes. Each disposable syringe contains 500 mg of cloxacillin as the benzathine salt in 7.5 g of suitable base.

Do Not Store Above 24°C (75°F)

Orbenin-DC™ is a trademark used by Intervet Inc.

Approved by FDA under NADA # 055-069

TAKE TIMEtime labelOBSERVE LABEL
DIRECTIONS

Manufactured by: G.C. Hanford Mfg. Co.
Syracuse, NY 13201

© 2015-2021 Intervet Inc., a subsidiary of Merck & Co., Inc., Madison, NJ 07940, US
All rights reserved.
Rev. 08/2021

359106 R3
PAL16270 01

MERCK
Animal Health

PRINCIPAL DISPLAY PANEL — 7.5 g Syringe Label

Orbenin-DC™
(cloxacillin benzathine intramammary infusion)
7.5 g

DRY COW

Long Acting Formula

Caution: Federal law restricts this drug to use by or on the order of a
licensed veterinarian. Approved by FDA under NADA # 055-069.

PRINCIPAL DISPLAY PANEL -- 7.5 g Syringe Label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — 7.5 g Syringe Carton

Orbenin-DC™
(cloxacillin benzathine
intramammary infusion)

DRY COW

Intramammary Infusion

short tip

LONG-ACTING FORMULA

Caution: Federal law restricts this drug to use by
or on the order of a licensed veterinarian.

12 single-dose (7.5 g),
disposable syringes

Approved by FDA under NADA # 055-069

MERCK
Animal Health

PRINCIPAL DISPLAY PANEL -- 7.5 g Syringe Carton
(click image for full-size original)
ORBENIN-DC
cloxacillin benzathine suspension
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:0061-8134
Route of Administration INTRAMAMMARY DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
cloxacillin benzathine (cloxacillin) cloxacillin 500 mg in 7.5 mL
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0061-8134-01 12 SYRINGE in 1 CARTON contains a SYRINGE
1 7.5 mL in 1 SYRINGE This package is contained within the CARTON (0061-8134-01)
2 NDC:0061-8134-06 144 SYRINGE in 1 PAIL contains a SYRINGE
2 7.5 mL in 1 SYRINGE This package is contained within the PAIL (0061-8134-06)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NADA NADA055069 03/11/1975
Labeler — Merck Sharp & Dohme Corp. (001317601)

Revised: 03/2023 Merck Sharp & Dohme Corp.

VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. VetLabel.com provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2024. All Rights Reserved.